This is the first study to confirm that BBR can reduce the risk of arrhythmia attacks after myocardial infarction by inhibiting the TGF-β1-induced transformation of CFS into myofibroblasts and directly inhibiting the secretion of NGF by myofibroblast cells. This evidence concerns the gene TGFB1 and cardiac arrhythmia.